We use cookies for a better user experience. Read our Privacy Policy

I Agree

Fragment-based Drug Discovery Market

Fragment-based Drug Discovery Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

Fragment-based Drug Discovery Market: Snapshot

The introduction of new techniques into the existing fragment-based drug discovery practices have created significant reductions in time and cost, driving the demand for such practices. Combinational chemistry and high-throughput screening are some of the more recently introduced practices that have helped make fragment-based drug discovery programs a lot faster and cheaper than before. 

Additionally, as the usage of fragment-based drug discovery grows in the field of discovering weaker inhibitors, biophysical techniques become extremely useful. These techniques can be used to measure binding within fragment compounds that possess low affinity for binding.

The demand for fragment-based drug discovery, however, is expected to be greatly hindered by the lowered potency of fragment screening, the most popular component, in certain compounds. The drugs generated have a lower than required potency, thus deterring several end users from approaching this technique.

The collective impact of all such drivers and restraints can be seen on the global fragment-based drug discovery market, which is expected to expand at a CAGR of 14.4% from 2015 to 2023 by revenue. By the end of 2016, this revenue is expected to reach US$435.6 mn and US$1.15 bn by the end of 2023.

North America Expected to Continue Leading Demand for Fragment-based Drug Discovery Programs

By the end of 2023, the market value of fragment-based drug discovery techniques in North America is expected to be 45.4% of the global market. While this is a drop in market value from its 2014 statistic, North America will still enjoy being a leading geographical segment for advancements in fragment-based drug discovery techniques.

The key factors responsible for the leading role of North America in fragment-based drug discovery programs is the high rate of research and development efforts undertaken by prominent market players in the region. The U.S. and Canada are both countries with advanced healthcare systems and infrastructures, and are often the base of advanced technological implementations, making North America the hub for the latest developments in fragment-based drug discovery.

This region is also ramping up its speed in development of fragment-based drug discovery techniques by employing outsourcing facilities from Asia Pacific. The demand for fragment-based drug discovery in Asia Pacific, on the other hand, is a lot higher than any other major region, owing to the rapid improvements in healthcare infrastructure and focus on better quality management in countries such as Japan and China.

Biopharmaceutical Companies Top the List of Fragment-based Drug Discovery Demand

Fragment-based drug discovery techniques have grown significantly in popularity in the recent years and have found a great scope of use in the biopharmaceuticals. This includes large companies, academic bodies, and CROs. These techniques have helped massively in creating chemical series that possess lead-like properties as they have improved the success rate of creation significantly over the conventional screening methods. Fragment-based drug discovery techniques have also been extremely useful in marking out chemical motifs from multiple targets.

It is a combination of all these factors that are expected to drive the use of fragment-based drug discovery in biopharmaceutical facilities to a revenue generation of US$565.2 mn by the end of 2023. The key providers of fragment-based drug discovery programs include Astex Pharmaceuticals, Charles River Laboratories International, Inc., Sygnature Discovery, Evotec A.G., and Beactica AB.

Fragment-based Drug Discovery Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes


Chapter 1 Preface 
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology 
1.4 Research Methodology: Assumptions 

Chapter 2 Executive Summary 
2.1 Global Fragment-based Drug Discovery Market, Estimates and Forecast, By Revenue, 2013–2023 (US$ Mn) 
2.2 Global Fragment-based Drug Discovery Market Revenue, by Services, 2014 (US$ Mn) 
2.3 Global Fragment-based Drug Discovery Market Revenue, by End-user, 2014 (US$ Mn) 
2.4 Global Market Share, by Geography, 2014 and 2023 (Value %) 
2.5 Fragment-based Drug Discovery Market Snapshot 

Chapter 3 Fragment-based Drug Discovery Market Overview 
3.1 Introduction 
      3.1.1 Hit to Lead  
      3.1.2 Progression to Candidates from Fragment Leads 
3.2 Event Impact Analysis 
3.3 Future Trends and Developments 
3.4 Market Drivers 
      3.4.1 Simpler and less time consuming technique 
      3.4.2 Streamlining and easy access to advanced biophysical techniques
3.5 Restraints 
      3.5.1 Lower level of potency in few of the compounds derived from fragment screening  
      3.5.2 Requirement of high protein and unique fragment library for conducting studies 
3.6 Opportunities 
      3.6.1 Merging of computational biology with biophysical techniques 
      3.6.2 Emerging economies to offer sustained growth opportunities 
3.7 Porter’s Five Forces Analysis 
3.8 Recent Developments in Fragment-based Drug Discovery 
3.9 Fragment-based Drug Discovery: Case Histories 
3.10 Market Share – Fragment-based Drug Discovery Market (2014) (%)  
3.11 Market Attractiveness Analysis – Fragment-based Drug Discovery Market 

Chapter 4 Market Segmentation – By Services Component 
4.1 Introduction 
4.2 Comparative Analysis of FBDD and HTS 
4.3 Global Fragment Screening Market Revenue for FBDD, 2013 – 2023 (US$ Mn) 
      4.3.1 Global Biophysical Techniques Market for FBDD (US$ Mn), 2013 – 2023) 
             4.3.1.1 Global NMR Spectroscopy Market Revenue for FBDD, 2013–2023 (US$ Mn) 
             4.3.1.2 Global DSF Assay Market Revenue for FBDD, 2013–2023 (US$ Mn) 
             4.3.1.3 Global Fluorescence Polarization (FP) Market Revenue for FBDD, 2013–2023 (US$ Mn) 
             4.3.1.4 Global Isothermal Titration Calorimetry (ITC) Market Revenue for FBDD, 2013–2023 (US$ Mn) 
             4.3.1.5 Global X-ray Crystallography Market Revenue for FBDD, 2013–2023 (US$ Mn) 
             4.3.1.6 Global SPR Market Revenue for FBDD, 2013–2023 (US$ Mn) 
             4.3.1.7 Global Biolayer Interferometry Market Revenue for FBDD, 2013–2023 (US$ Mn) 
             4.3.1.8 Global Mass Spectrometry (MS) Market Revenue for FBDD, 2013–2023 (US$ Mn) 
             4.3.1.9 Global Capillary Electrophoresis (CE) Market Revenue for FBDD, 2013–2023 (US$ Mn) 
             4.3.1.10 Global Other (Biochemical Assays) Market Revenue for FBDD, 2013–2023 (US$ Mn) 
      4.3.2 Global Non-biophysical Techniques Market Revenue for FBDD, 2013–2023 (US$ Mn) 
4.4 Global Fragment Optimization Market Revenue for FBDD, 2013–2023 (US$ Mn) 

Chapter 5 Market Segmentation – By End-user 
5.1 Introduction 
5.2 Global Market for Fragment-based Drug Discovery in Biopharmaceutical Companies, 2013–2023 (US$ Mn) 
5.3 Global Market for Fragment-based Drug Discovery in CROs, 2013–2023 (US$ Mn) 
5.4 Global Market for Fragment-based Drug Discovery in Academic and Research Institutions, 2013–2023 (US$ Mn) 

Chapter 6 Fragment-based Drug Discovery Market - Regional Analysis 
6.1 Global Overview 
6.2 North America Fragment-based Drug Discovery Market Overview 
      6.2.1 U.S. Fragment-based Drug Discovery Market Revenue, 2013 - 2023, (US$ Mn) 
      6.2.2 Canada Fragment-based Drug Discovery Market Revenue, 2013 – 2023, (US$ Mn) 
6.3 Europe Fragment-based Drug Discovery Market Overview 
      6.3.1 Germany Fragment-based Drug Discovery Market Revenue, 2013 - 2023, (US$ Mn) 
      6.3.2 U.K. Fragment-based Drug Discovery Market Revenue, 2013 – 2023, (US$ Mn) 
      6.3.3 Rest of Europe Fragment-based Drug Discovery Market Revenue, 2013–2023 (US$ Mn) 
6.4 Asia Pacific Fragment-based Drug Discovery Market Revenue, 2013–2023 (US$ Mn) 
      6.4.1 Japan Fragment-based Drug Discovery Market Revenue, 2013 - 2023, (US$ Mn) 
      6.4.2 Australia Fragment-based Drug Discovery Market Revenue, 2013 – 2023, (US$ Mn) 
      6.4.3 Rest of Asia Pacific Fragment-based Drug Discovery Market Revenue, 2013–2023 (US$ Mn) 
6.5 LATAM Fragment-based Drug Discovery Market Revenue, 2013–2023 (US$ Mn) 
      6.5.1 Brazil Fragment-based Drug Discovery Market Revenue, 2013 - 2023, (US$ Mn) 
      6.5.2 Rest of LATAM Fragment-based Drug Discovery Market Revenue, 2013 – 2023, (US$ Mn) 
6.6 RoW Fragment-based Drug Discovery Market Revenue, 2013–2023 (US$ Mn) 

Chapter 7 Company Profiles 
7.1 Astex Pharmaceuticals 
7.2 Alveus Pharmaceuticals Pvt. Ltd. 
7.3 Beactica AB 
7.4 Charles River Laboratories International, Inc. 
7.5 Crown Bioscience, Inc. 
7.6 Emerald BioStructures, Inc. 
7.7 Evotec AG 
7.8 Kinetic Discovery Limited
7.9 Proteros Fragments GmbH 
7.10 Sprint Bioscience 
7.11 Structure Based Design, Inc.  
7.12 Sygnature Discovery 

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

119

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved